

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/P00995D77D3EN.html>

Date: April 2018

Pages: 155

Price: US\$ 3,500.00 (Single User License)

ID: P00995D77D3EN

Abstracts

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H1 2018'; Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes.

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 1 (PARP-1) is an enzyme encoded by the PARP1 gene.

It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism.

It positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. It is required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites.

The report 'Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 5, 9, 1, 4 and 3 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology, Respiratory, Toxicology and Undisclosed which include indications Ovarian Cancer, Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Metastatic Breast Cancer, Small-Cell Lung Cancer, Solid Tumor, Gastric Cancer, Epithelial Ovarian Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Glioblastoma Multiforme (GBM), Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Cervical Cancer, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Transitional (Urothelial) Tract Cancer, Non-Hodgkin Lymphoma, Prostate Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Chronic Lymphocytic Leukemia, Bladder Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Germ Cell Tumors, Germinomatous (Seminomatous) Germ Cell Tumors, Glioma, Gynecological Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell

Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Laryngeal Cancer, Leiomyosarcoma, Lung Cancer, Lung Injury, Lung Transplant Rejection, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), Myelofibrosis, Neuroblastoma, Neuroendocrine Tumors, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Organophosphate and Carbamate Poisoning, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peritoneal Tumor, Polycythemia Vera, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Testicular Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Traumatic Brain Injury, Unspecified and Uveal Melanoma.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)

The report reviews Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP

Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects

The report assesses Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Overview

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development

AbbVie Inc

American Gene Technologies International Inc

AstraZeneca Plc

BeiGene Ltd

Checkpoint Therapeutics Inc

Clovis Oncology Inc

Hager Biosciences LLC

Ildong Pharmaceutical Co Ltd

IMPACT Therapeutics Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Mitsubishi Tanabe Pharma Corp

Nerviano Medical Sciences Srl

Shanghai Acebright Pharmaceuticals Group Co Ltd

Tasly Pharmaceutical Group Co Ltd

Tesaro Inc

Teva Pharmaceutical Industries Ltd

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Drug Profiles

2X-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABT-767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-PD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-0108 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1775 + olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-6738 + olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cediranib maleate + olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDX-1197 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-4297 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JPI-289 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-124 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

niraparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-118 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-293 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pamiparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rucaparib camsylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-10914 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-3162 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PARP-1 for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PARP1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOMCL-9112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tislelizumab + pamiparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSL-1502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veliparib ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZ-120312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YHP-743 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Dormant Products

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Discontinued Products

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Product Development Milestones

Featured News & Press Releases

Apr 06, 2018: Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer

Apr 03, 2018: The European Medicines Agency Accepts Regulatory Submission for Lynparza in BRCA-mutated HER2-Negative Metastatic Breast Cancer

Apr 02, 2018: Myriad Receives Pre-Market Approval for its BRACAnalysis Diagnostic System in Japan

Mar 26, 2018: Data from TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer

Mar 26, 2018: EMA Recommends Granting a Conditional Marketing Authorisation for Rucaparib

Mar 14, 2018: TESARO to Present Data on ZEJULA at AACR 2018 Annual Meeting

Mar 08, 2018: Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035

Feb 27, 2018: TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results

Feb 23, 2018: Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer

Feb 21, 2018: Clovis Oncology Receives Positive Trend Vote from CHMP in European Regulatory Review for Rucaparib Ovarian Cancer Treatment Indication

Feb 08, 2018: Once a day pill for ovarian cancer could be made available on the CDF

Feb 05, 2018: Newcastle University Provides Update on Anti-Neoplastic Agent Rucaparib

Jan 19, 2018: Lynparza receives approval in Japan for the treatment of advanced ovarian cancer

Jan 12, 2018: LYNPARZA (olaparib) Approved by US FDA in Germ line BRCA-mutated Metastatic Breast Cancer

Jan 03, 2018: Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Products under Development by Companies, H1 2018 (Contd.5), H1 2018
Products under Development by Companies, H1 2018 (Contd.6), H1 2018
Products under Development by Companies, H1 2018 (Contd.7), H1 2018
Products under Development by Companies, H1 2018 (Contd.8), H1 2018
Products under Development by Companies, H1 2018 (Contd.9), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AbbVie Inc, H1 2018
Pipeline by American Gene Technologies International Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by BeiGene Ltd, H1 2018
Pipeline by Checkpoint Therapeutics Inc, H1 2018
Pipeline by Clovis Oncology Inc, H1 2018
Pipeline by Hager Biosciences LLC, H1 2018
Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018
Pipeline by IMPACT Therapeutics Inc, H1 2018
Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Pipeline by Nerviano Medical Sciences Srl, H1 2018
Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H1 2018

Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018

Pipeline by Tesaro Inc, H1 2018

Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd.1), H1 2018

Dormant Products, H1 2018 (Contd.2), H1 2018

Discontinued Products, H1 2018

Discontinued Products, H1 2018 (Contd.1), H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

AbbVie Inc

American Gene Technologies International Inc

AstraZeneca Plc

BeiGene Ltd

Checkpoint Therapeutics Inc

Clovis Oncology Inc

Hager Biosciences LLC

Ildong Pharmaceutical Co Ltd

IMPACT Therapeutics Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Mitsubishi Tanabe Pharma Corp

Nerviano Medical Sciences Srl

Shanghai Acebright Pharmaceuticals Group Co Ltd

Tasly Pharmaceutical Group Co Ltd

Tesaro Inc

Teva Pharmaceutical Industries Ltd

I would like to order

Product name: Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/P00995D77D3EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P00995D77D3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970